menu

Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches

3 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Dive into the forefront of precision oncology with Drs. Pasi Janne and Jyoti Patel, where they unravel the potential of HER3-directed antibody-drug conjugates (ADCs) in revolutionizing treatment for NSCLC. Discover the transformative potential of HER3-directed ADCs in overcoming resistance to EGFR-targeted TKI therapies. This program offers a unique blend of trial results and practical strategies through the lens of a clinical case. Join us to lead the change in cancer care.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Pasi Jänne, MD
    Senior Vice President for Translational Medicine
    Dana-Farber Cancer Institute
    Boston, MA

    Dr. Jänne has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Consulting Fees: Abbvie, Accutar Biotech, Allorion Therapeutics, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Blueprint Medicines, Chugai Pharmaceuticals, Daiichi Sankyo, Duality Biologics, Eli Lilly, Esai, Frontier Medicines, Hongyun Biotechnology, Merus, Mirati Therapeutics, Monte Rosa, Novartis, Nuvalent, Pfizer, Roche/Genentech, Sanofi Pharmaceuticals, Scorpion Therapeutics, SFJ Pharmarceuticals, Silicon Therapeutics, Syndax, Takeda Oncology, Transcenta,Voronoi

    Research: AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, PUMA, Revolution Medicines, Takeda Oncology

    Patents, Royalties, Other Intellectual Property: LabCorp

    Jyoti Patel, MD
    Professor of Medicine
    Northwestern University
    Chicago, IL

    Dr. Patel has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Consulting Fees: AbbVie, AstraZeneca, Eli Lilly, Genentech, Takeda

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Brad Bongiovanni, ND has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • William Mencia, MD has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Bing Xu, PhD has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the biologic and clinical rationale for targeting HER3 and use of HER3-directed ADCs in NSCLC management
    • Evaluate clinical evidence for HER3-directed ADCs in patients who progress following TKIs or platinum-based chemotherapy in EGFR-mutant NSCLC
    • Integrate efficacy and safety data on HER3-directed agents and/or combinations into sequencing considerations for patients with progressive stage NSCLC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, oncology nurses, and oncology pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. Approval is valid until February 28, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for .50 contact hours/0.05 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is JA0006235-0000-24-015-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.   

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Dive into the forefront of precision oncology with Drs. Pasi Janne and Jyoti Patel, where they unravel the potential of HER3-directed antibody-drug conjugates (ADCs) in revolutionizing treatment for NSCLC. Discover the transformative potential of HER3-directed ADCs in overcoming resistance to EGFR-targeted TKI therapies. This program offers a unique blend of trial results and practical strategies through the lens of a clinical case. Join us to lead the change in cancer care.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Pasi Jänne, MD
    Senior Vice President for Translational Medicine
    Dana-Farber Cancer Institute
    Boston, MA

    Dr. Jänne has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Consulting Fees: Abbvie, Accutar Biotech, Allorion Therapeutics, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Blueprint Medicines, Chugai Pharmaceuticals, Daiichi Sankyo, Duality Biologics, Eli Lilly, Esai, Frontier Medicines, Hongyun Biotechnology, Merus, Mirati Therapeutics, Monte Rosa, Novartis, Nuvalent, Pfizer, Roche/Genentech, Sanofi Pharmaceuticals, Scorpion Therapeutics, SFJ Pharmarceuticals, Silicon Therapeutics, Syndax, Takeda Oncology, Transcenta,Voronoi

    Research: AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, PUMA, Revolution Medicines, Takeda Oncology

    Patents, Royalties, Other Intellectual Property: LabCorp

    Jyoti Patel, MD
    Professor of Medicine
    Northwestern University
    Chicago, IL

    Dr. Patel has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Consulting Fees: AbbVie, AstraZeneca, Eli Lilly, Genentech, Takeda

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Brad Bongiovanni, ND has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • William Mencia, MD has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Bing Xu, PhD has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the biologic and clinical rationale for targeting HER3 and use of HER3-directed ADCs in NSCLC management
    • Evaluate clinical evidence for HER3-directed ADCs in patients who progress following TKIs or platinum-based chemotherapy in EGFR-mutant NSCLC
    • Integrate efficacy and safety data on HER3-directed agents and/or combinations into sequencing considerations for patients with progressive stage NSCLC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, oncology nurses, and oncology pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. Approval is valid until February 28, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for .50 contact hours/0.05 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is JA0006235-0000-24-015-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.   

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule14 Apr 2024